Human cell chip predicts chemotherapy effects
Roche and US company Hesperos Inc have used human cancer and organ cells, placed in a 5-chamber microfluidic chip, to predict chemotherapy safety and efficacy preclinically.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2175 entries already.
Entries by Thomas Gabrielczyk
IL-10R-deficient macrophages trigger IBD
Researchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.
Breakthrough in liquid biopsy
German and US researchers have developed a diagnostic technique capable to detect one single circulating tumour cell in one litre of blood.
ADC Therapeutics raise $76m in Series E expansion
Swiss antibody drug conjugate developer ADC Therapeutics SA raised $76m, bringing the total gross proceeds to $276 million in its Series E financing.
Janssen and Genmab in licence option deal
Janssen Biotech Inc has inked a licence option contract with Genmab A/S on its next-generation anti CD38 antibody HexaBody®-CD38 and HexaBody platform technology.
HRP-Protector – for easy and safe long-term storage of HRP conjugates
HRP-Protector is a long-term stabilizer for horseradish peroxidase (HRP) coupled to antibodies or Neutravidin/Streptavidin.
Evotec bags US$23.8m to fight tuberculosis
The Bill & Melinda Gates Foundation has granted Evotec SE $23.8m to identify the best drug combos to fight tuberculosis.
How lungs trigger innate lymphoid cell dynamics
The cells’ surrounding structures play an important role as cues from the immune system in guiding their motility and behaviour, researchers from the UK and the US report.
Researchers find clue to Parkinson’s gene therapy
An enzyme that clears out alpha-synuclein from neurons may counteract Parkinson’s Disease, report researchers from ETH Zürich and Novartis.
Chikungunya vaccine developer Themis bags $21m
Under a partnering ageement with CEPI, Themis Bioscience will receive $21m to push pivotal testing of MV-CHIK, its Chikungunya vaccine candidate.